Animal models of idiopathic membranous nephropathy: Recent advances and future perspectives

Abstract

Idiopathic membranous nephropathy (IMN) is one of the main causes of adult nephrotic syndrome. A subset of untreated or inadequately treated patients eventually progress to end-stage renal disease (ESRD), posing a significant clinical challenge. Although the discovery of novel podocyte target antigens has deepened our understanding of IMN pathogenesis, the precise molecular mechanisms remain incompletely elucidated, and effective targeted therapies are still lacking. Animal models play an irreplaceable role in uncovering IMN pathogenesis and developing effective therapies. In recent years, with a deeper understanding of IMN, researchers have successfully established various animal models, including Heymann nephritis (HN), cationic bovine serum albumin (C-BSA), Aminopeptidase A (APA), thrombospondin type 1 domain-containing 7A (THSD7A)-related, and phospholipase A2 receptor (PLA2R)-related IMN models. These models have substantially advanced the simulation of pathological human IMN features. Notably, the development of human PLA2R1-related animal models marks a landmark breakthrough in this field, as these models are the first to recapitulate the immunopathological processes driven by a key human autoantigen in experimental animals. However, current animal models have their own limitations and still cannot fully replicate the complex pathological process of human IMN. This review summarizes recent progress in animal IMN models, analyzes their methods, pathological features, strengths, and limitations, and discusses future directions. Future model development should integrate advanced multi-omics and artificial intelligence (AI) to achieve greater accessibility and precision, enabling the construction of multidimensional models encompassing genetics, environment, and immunity, thereby enabling a leap from “disease simulation” to “personalized treatment”.

Keywords

animal model / end-stage renal disease / idiopathic membranous nephropathy / phospholipase A2 receptor

References

[1] Segal PE, Choi MJ. Recent advances and prognosis in idiopathic membranous nephropathy. Adv Chronic Kidney Dis. 2012; 19(2): 114-119.

[2] Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017; 91(3): 566-574.

[3] Alsharhan L, Beck LH Jr. Membranous nephropathy: core curriculum 2021. Am J Kidney Dis. 2021; 77(3): 440-453.

[4] Meena P, Ramachandran R, Bose B, Hissaria P, Das P. Changing treatment paradigms for membranous nephropathies. Nephrol Dial Transplant. 2024; 39(12): 1938-1941.

[5] Gan W, Zhu F, Zeng X, et al. The association between serum complement 4 and relapse of primary membranous nephropathy: a multicenter retrospective cohort study. Front Med (Lausanne). 2024; 11:1451677.

[6] Hullekes F, Uffing A, Verhoeff R, et al. Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study. Am J Transplant. 2024; 24(6): 1016-1026.

[7] Bai J, Zheng Z, Cao J, et al. Incidence and risk factors for recurrent membranous nephropathy after kidney transplantation: a systematic review and meta-analysis. Ann Med. 2025; 57(1):2522971.

[8] Bi J, Guo W, Ji P, Wang X, Xie Y. Diagnosis and treatment of membranous nephropathy in integrative medicine. Integr Med Nephrol Androl. 2024; 11(3):e23-00014.

[9] Miao H, Zhang Y, Yu X, Zou L, Zhao Y. Membranous nephropathy: systems biology-based novel mechanism and traditional Chinese medicine therapy. Front Pharmacol. 2022; 13:969930.

[10] Li M, Chen X, Li Q. Advances in the treatment of refractory membranous nephropathy with integrative medicine. Integr Med Nephrol Androl. 2025; 12(3):e24-00045.

[11] Jin Q, Zhan Y. Traditional Chinese medicine as a promising therapy for patients with membranous nephropathy. Integr Med Nephrol Androl. 2025; 12(3):e25-00020.

[12] Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015; 385(9981): 1983-1992.

[13] Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1): 11-21.

[14] Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014; 371(24): 2277-2287.

[15] Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020; 97(1): 163-174.

[16] Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020; 98(5): 1253-1264.

[17] Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol. 2021; 32(7): 1666-1681.

[18] Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy. J Am Soc Nephrol. 2021; 32(5): 1249-1261.

[19] Reinhard L, Machalitza M, Wiech T, et al. Netrin G1 is a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol. 2022; 33(10): 1823-1831.

[20] Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017; 12(6): 983-997.

[21] Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol. 2020; 15: 287-313.

[22] Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy. J Clin Med. 2021; 10(4):607.

[23] Li C, Li P, Guo W, et al. The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study. Korean J Intern Med. 2022; 37(1): 154-166.

[24] Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Prim. 2021; 7(1):69.

[25] Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol. 2020; 31(1): 208-217.

[26] Bose B, Carter SA, Abdy ME, et al. CARI guidelines commentary on the KDIGO clinical practice guideline for the management of glomerular diseases. Nephrology (Carlton). 2025; 30(9):e70119.

[27] Hamad S, Alkaales HM, Nassrullah R, Qasim RN, Qasim SN, Al-Mohammed A. Diagnostic accuracy of serum anti-phospholipase A2 receptor (PLA2R) antibody assays for membranous nephropathy in patients with nephrotic syndrome: a systematic review. Cureus. 2025; 17(11):e97957.

[28] Ragy O, Abass W, Kanigicherla DAK, et al. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrol Dial Transplant. 2025; 40(8): 1458-1469.

[29] Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. 1959; 100(4): 660-664.

[30] Sasaki O, Zhou W, Miyazaki M, et al. Intraglomerular C3 synthesis in rats with passive Heymann nephritis. Am J Pathol. 1997; 151(5): 1249-1256.

[31] Zhou W, Andrews PA, Wang Y, et al. Evidence for increased synthesis of complement C4 in the renal epithelium of rats with passive Heymann nephritis. J Am Soc Nephrol. 1997; 8(2): 214-222.

[32] Jiang HX, Feng Z, Zhu ZB, et al. Advances of the experimental models of idiopathic membranous nephropathy (review). Mol Med Rep. 2020; 21(5): 1993-2005.

[33] Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol. 1995; 6(1): 35-47.

[34] Makker SP, Tramontano A. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis—implications for the pathogenesis of idiopathic human membranous glomerulonephritis. J Pathol. 2006; 210(3): 282-287.

[35] Cunningham PN, Hack BK, Ren G, Minto AW, Morgan BP, Quigg RJ. Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney Int. 2001; 60(3): 900-909.

[36] Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun. 2023; 14(1):473.

[37] Gao S, Cui Z, Zhao MH. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J Am Soc Nephrol. 2022; 33(9): 1742-1756.

[38] Wang H, Lv D, Jiang S, et al. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction. Cell Death Dis. 2022; 13(3):281.

[39] Wang H, Liu H, Cheng H, et al. Klotho stabilizes the podocyte actin cytoskeleton in idiopathic membranous nephropathy through regulating the TRPC6/CatL pathway. Am J Nephrol. 2024; 55(3): 345-360.

[40] Chen B, Guan X, Gunning WT, et al. Negative modulation of B cell activation by melanocortin 1 receptor signaling protects against membranous nephropathy. J Am Soc Nephrol. 2023; 34(3): 467-481.

[41] Yang X, Wang Q, Bing B, et al. The role of neutrophils in venous thrombosis in primary membranous nephropathy. Am J Nephrol. 2025; 56(5): 630-640.

[42] Lin Z, Wang Z, Kim Thuong VP, et al. Sanqi Qushi formula ameliorates renal injury in experimental membranous nephropathy rats by inhibiting the MEK/ERK signaling pathway. J Ethnopharmacol. 2025; 348:119813.

[43] Wang Y, Shi M, Sheng L, et al. Shen-Qi-Di-Huang decoction induces autophagy in podocytes to ameliorate membranous nephropathy by suppressing USP14. J Ethnopharmacol. 2025; 340:119228.

[44] Prabakaran T, Nielsen R, Larsen JV, et al. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One. 2011; 6(9):e25065.

[45] Sun J, Hultenby K, Axelsson J, et al. Proximal tubular expression patterns of megalin and cubilin in proteinuric nephropathies. Kidney Int Rep. 2017; 2(4): 721-732.

[46] Batsford S, Oite T, Takamiya H, Vogt A. Anionic binding sites in the glomerular basement membrane: possible role in the pathogenesis of immune complex glomerulonephritis. Ren Physiol. 1980; 3(1–6): 336-340.

[47] Border WA, Ward HJ, Kamil ES, Cohen AH. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest. 1982; 69(2): 451-461.

[48] Kobayashi M, Muro K, Yoh K, et al. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. Nephrol Dial Transplant. 1998; 13(10): 2501-2508.

[49] Chen JS, Chen A, Chang LC, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. Nephrol Dial Transplant. 2004; 19(11): 2721-2728.

[50] Wu CC, Chen JS, Chen SJ, et al. Kinetics of adaptive immunity to cationic bovine serum albumin-induced membranous nephropathy. Kidney Int. 2007; 72(7): 831-840.

[51] Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005; 68(1): 302-310.

[52] Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011; 364(22): 2101-2110.

[53] Liu B, Lu R, Li H, et al. Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome. Phytomedicine. 2019; 59:152913.

[54] Nash AS, Mohammed NA, Wright NG. Experimental immune complex glomerulonephritis and the nephrotic syndrome in cats immunised with cationised bovine serum albumin. Res Vet Sci. 1990; 49(3): 370-372.

[55] Choi EW, Lee CW. Development of canine nephrotic syndrome model. J Vet Med Sci. 2004; 66(2): 169-174.

[56] Ma M, Pan Y, Zhang Y, et al. Metformin combined with rapamycin ameliorates podocyte injury in idiopathic membranous nephropathy through the AMPK/mTOR signaling pathway. J Cell Commun Signal. 2023; 17(4): 1405-1415.

[57] Wang W, Sheng L, Chen Y, et al. Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine. 2022; 96:153886.

[58] Liu B, Wang D, Cao Y, et al. MitoTEMPO protects against podocyte injury by inhibiting NLRP3 inflammasome via PINK1/Parkin pathway-mediated mitophagy. Eur J Pharmacol. 2022; 929:175136.

[59] Wang YN, Miao H, Yu XY, et al. Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy. Free Radic Biol Med. 2023; 207: 89-106.

[60] Miao H, Wang YN, Su W, et al. Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway. Acta Pharmacol Sin. 2024; 45(1): 137-149.

[61] Miao H, Wang YN, Yu XY, et al. Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites. Br J Pharmacol. 2024; 181(1): 162-179.

[62] Zhao X, Liu Z, Wu C. Gut microbiota and membranous nephropathy: novel molecular mechanisms and natural product therapeutic strategies. Integr Med Nephrol Androl. 2025; 12(4):e24-00062.

[63] Assmann KJ, van Son JP, Dijkman HB, Koene RA. A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection. J Exp Med. 1992; 175(3): 623-635.

[64] Dijkman HB, Gerlofs-Nijland ME, van der Laak JA, Wetzels JF, Groenen PJ, Assmann KJ. Podocyte changes after induction of acute albuminuria in mice by anti-aminopeptidase A mAb. Nephron Exp Nephrol. 2003; 94(3): e85-e93.

[65] Natori Y, Shindo N, Natori Y. Proteinuria induced by anti-dipeptidyl peptidase IV (gp108); role of circulating and glomerular antigen. Clin Exp Immunol. 1994; 95(2): 327-332.

[66] Meyer TN, Schwesinger C, Wahlefeld J, et al. A new mouse model of immune-mediated podocyte injury. Kidney Int. 2007; 72(7): 841-852.

[67] Meyer-Schwesinger C, Dehde S, Klug P, et al. Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis. J Immunol. 2011; 187(6): 3218-3229.

[68] Pedchenko V, Kitching AR, Hudson BG. Goodpasture's autoimmune disease—a collagen IV disorder. Matrix Biol. 2018; 71-72: 240-249.

[69] Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol. 2009; 20(7): 1471-1479.

[70] Zhang JJ, Malekpour M, Luo W, et al. Murine membranous nephropathy: immunization with α3(IV) collagen fragment induces subepithelial immune complexes and FcγR-independent nephrotic syndrome. J Immunol. 2012; 188(7): 3268-3277.

[71] Hopfer H, Holzer J, Hünemörder S, et al. Characterization of the renal CD4+ T-cell response in experimental autoimmune glomerulonephritis. Kidney Int. 2012; 82(1): 60-71.

[72] Luo W, Olaru F, Miner JH, et al. Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy. Front Immunol. 2018; 9:1433.

[73] Hopfer H, Maron R, Butzmann U, Helmchen U, Weiner HL, Kalluri R. The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASEB J. 2003; 17(8): 860-868.

[74] Maruyama S, Cantu E 3rd, Demartino C, et al. Membranous glomerulonephritis induced in the pig by antibody to angiotensin-converting enzyme: considerations on its relevance to the pathogenesis of human idiopathic membranous glomerulonephritis. J Am Soc Nephrol. 1999; 10(10): 2102-2108.

[75] Herwig J, Skuza S, Sachs W, et al. Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes. J Am Soc Nephrol. 2019; 30(5): 824-839.

[76] Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016; 126(7): 2519-2532.

[77] Wang Z, Wen L, Dou Y, Zhao Z. Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway. Biosci Rep. 2018; 38(3):BSR20180131.

[78] Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. J Am Soc Nephrol. 2017; 28(11): 3262-3277.

[79] Pan Y, Wan J, Liu Y, et al. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci Rep. 2014; 4:6660.

[80] Liu W, Gao C, Dai H, et al. Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role. Front Immunol. 2019; 10:1809.

[81] Meyer-Schwesinger C, Tomas NM, Dehde S, et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int. 2020; 97(5): 913-919.

[82] Tomas NM, Dehde S, Meyer-Schwesinger C, et al. Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice. Kidney Int. 2023; 103(2): 297-303.

[83] Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. 2015; 26(2): 302-313.

[84] Reinhard L, Zahner G, Menzel S, Koch-Nolte F, Stahl RAK, Hoxha E. Clinical relevance of domain-specific phospholipase A(2) receptor 1 antibody levels in patients with membranous nephropathy. J Am Soc Nephrol. 2020; 31(1): 197-207.

[85] Tomas NM, Schnarre A, Dehde S, et al. Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy. Kidney Int. 2023; 104(5): 916-928.

[86] Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol. 2015; 26(2): 291-301.

[87] Seitz-Polski B, Dolla G, Payré C, et al. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. 2016; 27(5): 1517-1533.

[88] Reinhard L, Wiech T, Reitmeier A, et al. Pathogenicity of human anti-PLA 2 R1 antibodies in minipigs: a pilot study. J Am Soc Nephrol. 2023; 34(3): 369-373.

[89] Dhaouadi T, Riahi A, Abdallah TB, Gorgi Y, Sfar I. Association of 10 polymorphisms in PLA2R1 and HLA DQA1 genes with primary membranous nephropathy risk: a meta-analysis and a meta-regression. Biomark Insights. 2024; 19:11772719241259602.

[90] Wang X, Yao K, Niu Y, Dong Z, Liang S. A new perspective on predicting PLA2R-associated membranous nephropathy relapse: the value of a genetic risk score. J Inflamm Res. 2026; 19:583141.

[91] Bajcsi D, Maróti Z, Endreffy E, Légrády P, Ábrahám G, Iványi B. The presence of risk and protective HLA-DQ haplotype combinations and PLA2R1 risk SNP in Hungarian patients with membranous nephropathy. Int J Mol Sci. 2025; 26(17):8621.

[92] Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016; 27(12): 3739-3746.

[93] Zhang W, Chen J, Yuan Y, Luo J, Zhou Z, Wang G. PM2.5-induced oxidative stress upregulates PLA2R expression in the lung and is involved in the pathogenesis of membranous nephropathy through extracellular vesicles. Front Pharmacol. 2024; 15:1516111.

[94] Zhang P, Huang W, Zheng Q, et al. A novel insight into the role of PLA2R and THSD7A in membranous nephropathy. J Immunol Res. 2021; 2021:8163298.

[95] Kistler AD, Salant DJ. Complement activation and effector pathways in membranous nephropathy. Kidney Int. 2024; 105(3): 473-483.

[96] Cai A, Meng Y, Zhou H, et al. Podocyte pathogenic bone morphogenetic protein-2 pathway and immune cell behaviors in primary membranous nephropathy. Adv Sci (Weinh). 2024; 11(29):e2404151.

[97] Zahner G, Dehde S, Seifert L, et al. Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice. Kidney Int. 2025; 108(6): 1179-1183.

[98] Huang M, Lassé M, Dehde S, et al. Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy. JCI Insight. 2026; 11:e198363.

[99] Wu J, Zhang Q, Du Y, et al. Detection and prognostic relevance of PLA2R epitopes in idiopathic membranous nephropathy: a simultaneous quantitative multiplex suspension array detection method. Clin Kidney J. 2025; 18(3):sfaf010.

[100] Salant DJ. Does epitope spreading influence responsiveness to rituximab in PLA2R-associated membranous nephropathy? Clin J Am Soc Nephrol. 2019; 14(8): 1122-1124.

[101] Strizzi CT, Ambrogio M, Zanoni F, et al. Epitope spreading in immune-mediated glomerulonephritis: the expanding target. Int J Mol Sci. 2024; 25(20):11096.

[102] Manral P, Caza TN, Storey AJ, Beck LH Jr, Borza DB. The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly IgG4 in membranous nephropathy. Front Immunol. 2022; 13:952235.

[103] Han M, Wang Y, Huang X, et al. Identification of hub genes and their correlation with immune infiltrating cells in membranous nephropathy: an integrated bioinformatics analysis. Eur J Med Res. 2023; 28(1):525.

[104] Shi M, Wang Y, Zhang H, et al. Single-cell RNA sequencing shows the immune cell landscape in the kidneys of patients with idiopathic membranous nephropathy. Front Immunol. 2023; 14:1203062.

[105] Duan X, Lv X, Wang X, et al. Impact of immune cell metabolism on membranous nephropathy and prospective therapy. Commun Biol. 2025; 8(1):405.

[106] Rafiq Z, Bashir T, Lu W, Puebla-Osorio N. Integrating AI, machine learning, and animal models for precision oncology: bridging preclinical and clinical gaps. ACS Pharmacol Transl Sci. 2025; 8(10): 3677-3683.

[107] Ghosh A, Choudhary G, Medhi B. The pivotal role of artificial intelligence in enhancing experimental animal model research: a machine learning perspective. Indian J Pharm. 2024; 56(1): 1-3.

[108] Khan A, Yen FS, Unlu G, et al. Machine-learning-guided discovery of SLC25A45 as a mediator of mitochondrial methylated amino acid import and carnitine synthesis. Cell Metab. 2025; 37(11): 2220-2232.e8.

[109] Destere A, Teisseyre M, Merino D, et al. Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence. Kidney Int Rep. 2024; 9(1): 134-144.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.